官方服务：
资源简介：
Sensor amplicon and RNA sequencing characterizing the genetic drivers of resistance to KRAS inhibitors
本数据集采用传感器扩增子（Sensor amplicon）测序与RNA测序（RNA sequencing）技术，对KRAS抑制剂耐药性的遗传驱动因素进行表征
应用场景：
创建时间：
2025-07-21
相关数据集
THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14
THREE-DIMENSIONAL STRUCTURES OF DRUG-RESISTANT MUTANTS OF HUMAN RHINOVIRUS 14 Descriptor: 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, HUMAN RHINOVIRUS 14 COAT PROTEIN (SUBUNIT VP1), HUMAN RHINOVIRUS 14
Protein Data Bank Japan2024-05-22 更新40
Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response [Tru-seq]
To investigate the transcriptomic changes associated with KRAS G12C inhibitor Adagrasib resistance and Adagrasib + SOS1 inhibitor (BI-3406) or Adagrasib + EGFR inhibitor (Cetuximab) combination treatm
NIAID Data Ecosystem20
Genome-Wide CRISPR Screen Identifies Multiple Synthetic Lethal Targets That Enhance KRAS (G12C) Inhibitor Efficacy [CRISPR]. Genome-Wide CRISPR Screen Identifies Multiple Synthetic Lethal Targets That Enhance KRAS (G12C) Inhibitor Efficacy [CRISPR]
KRAS G12C inhibitors (G12Ci) alone and in various combinations are being tested in multiple tumors with over-activation of the RAS/ERK pathway. KRAS plays a critical role in normal cell signaling; hen
NIAID Data Ecosystem10
RAS-GTP inhibition overcomes acquired resistance to KRASG12C inhibitors mediated by oncogenic and wildtype RAS activation in NSCLC preclinical models: H358 AMG510 Resistance
Small molecule KRASG12C(OFF) inhibitors that bind to the inactive GDP-bound state of KRAS have demonstrated efficacy in patients with KRASG12C mutant tumors, yet responses tend to be transient due to
NIAID Data Ecosystem40
Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response (Quant-Seq 2)
To investigate the transcriptomic changes associated with KRAS G12C inhibitor Adagrasib resistance and Adagrasib + SOS1 inhibitor (BI-3406) or Adagrasib + EGFR inhibitor (Cetuximab) combination treatm
NIAID Data Ecosystem20
